AOTI (AOTI) H2 2025 earnings summary

Executive summary

• Achieved 14% year-over-year revenue growth to $66.5 million in FY25, outpacing the advanced wound care devices market despite U.S. healthcare headwinds.

• Focuses on healing chronic wounds with a unique, clinically proven topical wound oxygen therapy, aiming to save limbs and improve patient lives.

• Maintains a differentiated, outcomes-based at-home care platform, with expanding payer endorsements and market access.

• CMS Medicare coverage determination is expected to be transformational, potentially expanding the serviceable market 65-fold to $26 billion.

• Expanded provider IDs in 19 states and secured coverage from major insurers, including Cigna, California Medicaid, ECRI, G-BA (Germany), NICE (UK), and NHS Supply Chain.

Financial highlights

• Revenue grew 14% year-over-year to $66.5 million; underlying growth outside Arizona was 15%.

• Adjusted EBITDA decreased to $7.5 million, with margin at 11.3%.

• Profit before tax was $3 million, reversing a prior year loss of $0.9 million; net profit reached $2.7 million.

• Receivables increased to $21.8 million, mainly due to Arizona Medicaid payment delays.

• Net debt position of $6.5 million at year-end, reflecting an $11 million SWK loan drawdown.

Outlook and guidance

• FY26 expected to be a transitional year with low single-digit revenue growth overall; core growth (excluding Arizona) expected in the mid-teens%.

• Adjusted EBITDA margin projected to be in the high single digits.

• Broader CMS Medicare coverage could expand the addressable market to $26 billion.

• Confident in sufficient cash headroom for the next 12 months, even in downside scenarios.

• Disruption in U.S. healthcare expected to persist through 2026, but growth trend improving.